Biography
Dr. Robin Kate Kelley is a gastrointestinal oncologist who specializes in cancers arising from the liver, including hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), and gallbladder carcinoma. Her research interests include developing clinical trials of new treatments and combination therapies for these cancers, including immunotherapy approaches as well as translational research to identify molecular and genetic biomarkers of response. Dr. Kelley graduated from the David Geffen School of Medicine at UCLA and completed a residency at UCLA, where she was chief resident in internal medicine. She then completed a fellowship in hematology and oncology at UCSF.
Dr. Kelley received an American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Merit Award in 2009, an ASCO Young Investigator Award in 2010, and the National Cancer Institute Cancer Clinical Investigator Team Leadership Award in 2014. She has authored numerous publications about treatments for advanced liver and bile duct cancers. She is involved in many organizations dedicated to improving the outcomes for patients with primary liver cancers, including National Comprehensive Cancer Network (NCCN) guideline panel for Liver Cancers, the National Cancer Institute Hepatobiliary Cancer Task Force, the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board, and the International Liver Cancer Association Education Committee.
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
University of California San Francisco | Fellowship | Hematology/Oncology | 10/2009 |
University of California Los Angeles | Chief Residency | Internal Medicine | 06/2006 |
University of California Los Angeles | Residency | Internal Medicine | 05/2005 |
University of California Los Angeles | M.D. | School of Medicine | 05/2002 |
Harvard College | A.B. | Biochemical Sciences | 05/1997 |
Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine: Medical Oncology - Subspecialty
Clinical Expertise
Colon Cancer
Hepatocellular Carcinoma (Liver Cancer)
Liver Metastases
Pancreatic Cancer
Rectal Cancer
Stomach Cancer
Clinical Trials
- Related Conditions: Biliary Tract Cancer, Cholangiocarcinoma, Bladder Cancer, Ampullary Cancer| Start Date: | End Date:
Program Affiliations
UCSF Helen Diller Family Comprehensive Cancer Center
Research Interests
Anal Cancer
Colorectal Cancer
Hepatocellular Carcinoma (Liver Cancer)
Liver Metastases
Rectal Cancer
Molecular Markers in Solid Tumors
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 123
- Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.| | View in PubMed
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.| | View in PubMed
- Author Correction: Hepatocellular carcinoma.| | View in PubMed
- Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma.| | View in PubMed
- Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.| | View in PubMed
- Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).| | View in PubMed
- Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma.| | View in PubMed
- Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.| | View in PubMed
- Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.| | View in PubMed
- Polyunsaturated Fatty Acid-Bound α-Fetoprotein Promotes Immune Suppression by Altering Human Dendritic Cell Metabolism.| | View in PubMed
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.| | View in PubMed
- Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.| | View in PubMed
- Immunology and immunotherapy of cholangiocarcinoma.| | View in PubMed
- Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.| | View in PubMed
- Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review.| | View in PubMed
- The evolving role of combination systemic therapies in hepatocellular carcinoma.| | View in PubMed
- What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature.| | View in PubMed
- The Evolving Role of Combination Systemic Therapies in Hepatocellular Carcinoma.| | View in PubMed
- Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis.| | View in PubMed
- Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.| | View in PubMed
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.| | View in PubMed
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.| | View in PubMed
- Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.| | View in PubMed
- Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.| | View in PubMed
- Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.| | View in PubMed
- Biliary cancer brain metastases: a multi-institution case series with case reports.| | View in PubMed
- Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.| | View in PubMed
- Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis.| | View in PubMed
- Discovering dominant tumor immune archetypes in a pan-cancer census.| | View in PubMed
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.| | View in PubMed
- Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.| | View in PubMed
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.| | View in PubMed
- Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.| | View in PubMed
- Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.| | View in PubMed
- Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling.| | View in PubMed
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.| | View in PubMed
- Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.| | View in PubMed
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.| | View in PubMed
- Hepatocellular Carcinoma - Origins and Outcomes.| | View in PubMed
- Cabozantinib: An evolving therapy for hepatocellular carcinoma.| | View in PubMed
- Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.| | View in PubMed
- Hepatocellular carcinoma.| | View in PubMed
- Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.| | View in PubMed
- Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.| | View in PubMed
- Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.| | View in PubMed
- Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.| | View in PubMed
- Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.| | View in PubMed
- Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer.| | View in PubMed
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.| | View in PubMed
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.| | View in PubMed
- Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma.| | View in PubMed
- Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.| | View in PubMed
- Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.| | View in PubMed
- Systemic therapies for intrahepatic cholangiocarcinoma.| | View in PubMed
- Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma.| | View in PubMed
- Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.| | View in PubMed
- Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.| | View in PubMed
- Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.| | View in PubMed
- Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.| | View in PubMed
- Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.| | View in PubMed
- Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.| | View in PubMed
- Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.| | View in PubMed
- Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.| | View in PubMed
- TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.| | View in PubMed
- Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.| | View in PubMed
- Heterogeneous Uptake of 18F-FDG and 68Ga-PSMA-11 in Hepatocellular Carcinoma.| | View in PubMed
- An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.| | View in PubMed
- Emerging Role for Systemic Therapy in Earlier Stages of HCC.| | View in PubMed
- Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype.| | View in PubMed
- Cabozantinib in Hepatocellular Carcinoma.| | View in PubMed
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.| | View in PubMed
- Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.| | View in PubMed
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.| | View in PubMed
- Cholangiocarcinoma - evolving concepts and therapeutic strategies.| | View in PubMed
- Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.| | View in PubMed
- Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.| | View in PubMed
- Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.| | View in PubMed
- NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.| | View in PubMed
- Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.| | View in PubMed
- Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.| | View in PubMed
- Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience.| | View in PubMed
- Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.| | View in PubMed
- Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.| | View in PubMed
- Biliary cancer: Utility of next-generation sequencing for clinical management.| | View in PubMed
- A phase II study of axitinib in advanced neuroendocrine tumors.| | View in PubMed
- A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.| | View in PubMed
- A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.| | View in PubMed
- Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.| | View in PubMed
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.| | View in PubMed
- A 46-Year-Old Asian Woman With Liver Mass.| | View in PubMed
- Biliary Tract Cancers: Finding Better Ways to Lump and Split.| | View in PubMed
- A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.| | View in PubMed
- Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.| | View in PubMed
- Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?| | View in PubMed
- Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.| | View in PubMed
- Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.| | View in PubMed
- A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.| | View in PubMed
- Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.| | View in PubMed
- Hepatobiliary cancers, version 2.2014.| | View in PubMed
- Genomic sequencing: assessing the health care system, policy, and big-data implications.| | View in PubMed
- 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.| | View in PubMed
- A review of hepatocellular carcinoma (HCC) staging systems.| | View in PubMed
- A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.| | View in PubMed
- Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.| | View in PubMed
- Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.| | View in PubMed
- Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.| | View in PubMed
- Novel therapeutics in hepatocellular carcinoma: how can we make progress?| | View in PubMed
- Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.| | View in PubMed
- Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial.| | View in PubMed
- Predictive biomarkers in advance of a companion drug: ahead of their time?| | View in PubMed
- Multidisciplinary management of hepatocellular carcinoma.| | View in PubMed
- Biomarker use in colorectal cancer therapy.| | View in PubMed
- NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.| | View in PubMed
- Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: a new strategy?| | View in PubMed
- Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?| | View in PubMed
- "And what other medications are you taking?".| | View in PubMed
- Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.| | View in PubMed
- KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic.| | View in PubMed
- Nonadherence to imatinib during an economic downturn.| | View in PubMed
- A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.| | View in PubMed
- Drug development in advanced colorectal cancer: challenges and opportunities.| | View in PubMed
- Sorafenib in hepatocellular carcinoma: separating the hype from the hope.| | View in PubMed
- Erlotinib in the treatment of advanced pancreatic cancer.| | View in PubMed